Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs

PARIS, FRANCE, 24 April 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Sandra Silvestri, M.D., Ph.D., as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs, effective 5 May 2023. She will serve on the Executive Leadership Team (ELT) and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew.

“Along with the ELT, I am very pleased to welcome Sandra to Ipsen. Her deep experience in every aspect of Medical will be critical as we continue to broaden our pipeline while delivering our specialty medicines to even more people around the world,” said David Loew, CEO, Ipsen.

Sandra brings years of extensive medical experience in the global biopharmaceutical industry and joins Ipsen after spending eight years at Sanofi. Since 2020, she has served as Senior Vice President and Chief Medical Officer of the General Medicines Global Business Unit, and Global Head of Medical Affairs Capabilities Centre of Excellence and Medical Hub, where she was responsible for worldwide medical affairs strategy and execution. She also represented Medical in the Company Executive Compliance Committee. Previously, for over a decade, Sandra held numerous national and international roles at Eli Lilly across R&D and Scientific Communications, and as Regional Medical Director, where she led strategic transformation projects.

“I’m inspired by Ipsen’s ambitious innovation agenda and vision to serve physicians and patients in areas of high unmet need around the world,” said Sandra. “I am honored to join as Chief Medical Officer and I look forward to working with my new colleagues at Ipsen.”

Sandra is a medical doctor who specialized in endocrinology and metabolic diseases. She holds a postdoctoral fellowship in emergency medicine, a Ph.D. in internal medicine and cardiovascular disease, and a Master’s degree in genetics and pharmacogenetics of bone mineral disorders. She speaks Italian, English, French.

Steven Hildemann, M.D., Ph.D., who served as Ipsen’s Chief Medical Officer for three years and successfully led a deep transformation of Global Medical Affairs and Patient Safety, will leave Ipsen to pursue other opportunities after handing over to Sandra.  

ENDS

About Ipsen 
Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With total sales of €3.0bn in FY 2022, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen has around 5,000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com 

For further information:

Contacts Investors
Craig Marks Vice President, Investor Relations +44 (0)7584 349 193
Media
Amy Wolf VP, Head of Corporate Brand Strategy & Communications +41 79 576 07 23	Ioana Piscociu Senior Manager Global Media Relations +33 6 69 09 12 96

Ipsen’s forward-looking statements

The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com.

 

Attachment

• Ipsen_CMO Announcement_Press Release_042023